Applied Therapeutics, Inc. (APLT)

NASDAQ: APLT · Delayed Price · USD
3.17
-0.23 (-6.76%)
At close: Jan 21, 2022 4:00 PM
3.21
0.04 (1.26%)
After-hours:Jan 21, 2022 5:08 PM EST
Market Cap83.10M
Revenue (ttm)n/a
Net Income (ttm)-102.11M
Shares Out26.22M
EPS (ttm)-4.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume347,230
Open3.30
Previous Close3.40
Day's Range3.13 - 3.44
52-Week Range3.13 - 29.80
Beta0.90
AnalystsBuy
Price Target31.83 (+904.1%)
Earnings Daten/a

About APLT

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III ...

IndustryBiotechnology
IPO DateMay 14, 2019
Employees27
Stock ExchangeNASDAQ
Ticker SymbolAPLT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for APLT stock is "Buy." The 12-month stock price forecast is 31.83, which is an increase of 904.10% from the latest price.

Price Target
$31.83
(904.10% upside)
Analyst Consensus: Buy

News

APPLIED THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Applied Therapeutics, Inc. on Behalf of Appl...

NEW YORK--(BUSINESS WIRE)-- #Applied--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Applied Therapeutics, Inc. (“Applied The...

2 days ago - Business Wire

APLT INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Applied Therapeutics, Inc. (APLT) Investors t...

SAN FRANCISCO, Jan. 14, 2022 /PRNewswire/ -- Hagens Berman urges Applied Therapeutics, Inc. (NASDAQ: APLT) investors with significant losses to submit your losses now. The firm is investigating possible...

1 week ago - PRNewsWire

SHAREHOLDER ALERT: Robbins LLP Investigates Applied Therapeutics, Inc. (APLT) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)---- $APLT #classactioninvestigation--Applied Therapeutics, Inc. (APLT) Holds Submission of New Drug Application for AT-007

1 week ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Applied Therapeutics, Inc. (APLT) Investigation

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. (“Applied Therapeutics” or the...

2 weeks ago - Business Wire

Berman Tabacco Announces Investigation of Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations

Boston, Massachusetts--(Newsfile Corp. - January 4, 2022) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Applied Therapeutics, Inc...

2 weeks ago - Newsfile Corp

Why Applied Therapeutics Stock Is Sliding Today

The company's lead candidate, AT-007, is going to take a lot longer to reach patients than expected.

2 weeks ago - The Motley Fool

Why Applied Therapeutics Shares Are Falling Today

Applied Therapeutics (NASDAQ: APLT) is trading significantly lower Monday after the company said it would not immediately submit a new drug application for its AT-007 for treatment of galactosemia. The ...

2 weeks ago - Benzinga

Applied Therapeutics To Hold Filing FDA Application For AT-007 In Rare Metabolic Disorder

Following discussions with the FDA, Applied Therapeutics Inc (NASDAQ: APLT) has decided to hold on submitting a marketing application for AT-007 for Galactosemia pending additional talks with the agency...

2 weeks ago - Benzinga

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

2 weeks ago - GlobeNewsWire

Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

1 month ago - GlobeNewsWire

Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism

NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

2 months ago - GlobeNewsWire

Applied Therapeutics Reports Third Quarter 2021 Financial Results

Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol

2 months ago - GlobeNewsWire

Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids

Substantial and statistically significant reduction in plasma galactitol of 40% with new weight-based dosing parameters

3 months ago - GlobeNewsWire

Applied Therapeutics Inc. (APLT) Upgraded to Buy: Here's Why

Applied Therapeutics Inc. (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago - Zacks Investment Research

Applied Therapeutics Stock Drops On Delayed NDA Submission For Its Lead Candidate

Applied Therapeutics Inc (NASDAQ: APLT) has reported initial biomarker data from the pediatric ACTION-Galactosemia Kids study and baseline analysis of the 47 children enrolled in the study. Related Cont...

4 months ago - Benzinga

Applied Therapeutics Reports Second Quarter 2021 Financial Results

NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing

5 months ago - GlobeNewsWire

Applied Therapeutics Added to Russell Microcap® Index

NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

6 months ago - GlobeNewsWire

Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientif...

~1 in 5 people with diabetes or pre-diabetes have Diabetic Cardiomyopathy, a serious and progressive disease that limits the heart's ability to function   People with diabetes or pre-diabetes who have D...

6 months ago - GlobeNewsWire

Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions ...

NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

7 months ago - GlobeNewsWire

Applied Therapeutics Stock Moves Higher On FDA Fast Track Review For AT-007 In Rare Metabolic Disorder

The FDA has granted Fast Track designation to Applied Therapeutics Inc's (NASDAQ: APLT) AT-007 to treat Galactosemia, a rare metabolic disease. AT-007 is the Company's central nervous system-penetrant A...

7 months ago - Benzinga

Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

7 months ago - GlobeNewsWire

Applied Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

7 months ago - GlobeNewsWire

Applied Therapeutics to Present at the UBS Global Healthcare Virtual Conference

NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecula...

8 months ago - GlobeNewsWire

Applied Therapeutics Reports First Quarter 2021 Financial Results

Phase 2 pilot study of AT-007 initiated in patients with SORD Deficiency

8 months ago - GlobeNewsWire

Applied Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results

AT-007 ACTION-Galactosemia Kids pediatric clinical study recently resumed following discussions with FDA

10 months ago - GlobeNewsWire